SYNTHESIS OF IODINATED AND RADIOIODINATED (E)-N-(3-IODOPROP-2-ENYL)-2β-CARBOMETHOXY-3β-(3', 4'-DICHLOROPHENYL) NORTROPANE (β-CDIT): A LIGAND FOR THE DOPAMINE TRANSPORTER.

P. Emond, M. Boazi, A. Duchêne[†], S. Chalon, J. C. Besnard, D. Guilloteau, Y. Frangin*.

INSERM U316, Laboratoire de Biophysique Médicale et Pharmaceutique, Faculté des Sciences Pharmaceutiques, Université François Rabelais, 31 avenue Monge, 37200 Tours, France.

[†] Laboratoire de Physicochimie des Interfaces et des Milieux Réactionnels (CEA 2098), Faculté des Sciences de Tours, Parc de Grandmont, 37200 Tours, France.

SUMMARY

The synthesis of (E)-N-(3-iodoprop-2-enyl)-2β-carbomethoxy-3β-(3', 4'-dichlorophenyl) nortropane (β-CDIT) and its radioiodinated analogues is described. Three different synthetic methods are reported for the preparation of (E)-N-[3-(tributylstannyl)-2-enyl]-2β-carbomethoxy-3β-(3', 4'-dichlorophenyl) nortropane, which was iododestannylated for the preparation of the corresponding iodinated derivative. We also report the radiolabelling of ß-CDIT with ^{125}I or ^{123}I that could be used for *in vitro* and *in vivo* exploration of the dopamine transporter.

*Correspondence.

INTRODUCTION

The use of human brain exploration by Single Photon Emission Tomography (SPET) has greatly increased within the last years due to the successful development of new ligands labelled with single photon emitting radionuclides (e.g. iodine-123). In particular, radioiodinated ligands with high affinity and specificity for the dopamine reuptake site are of great interest for better understanding of the physiological and pathophysiological processes of central dopaminergic neurotransmission. Moreover, the availability of these new SPECT tracers should allow diagnosis and treatment evaluation of neurological and neuropsychiatric disorders such as Parkinson's disease (1), Alzheimer's disease (2) and schizophrenia (3) in atraumatic conditions. Several radiochemical probes with a modified cocaine structure have been reported for the characterization of the cocaine binding site on the dopamine transporter (4-10). For example (E)-N-(3-iodoprop-2-enyl)-2β-carbomethoxy-3β-(4'-chlorophenyl) nortropane (IPT) is a specific *in vivo* dopamine reuptake agent (6). However this tropane derivative exhibits high serotonin transporter affinity *in vitro* leading to discrepancies in *in vivo* results (10). Based on these results, we conceived a new iodinated ligand, (E)-N-(3-iodoprop-2-enyl)-2β-carbomethoxy-3β-(3', 4'-dichlorophenyl) nortropane (β-CDIT), and demonstrated its potential use as a specific dopamine transporter reuptake agent (11). In addition, preliminary SPECT imaging on non-human primates has revealed that ß-CDIT should be a potential ligand for SPECT exploration of the dopamine transporter (12). We report here the full synthesis of β-CDIT starting from (-) cocaine. We also describe the preparation of the tributyltin precursor by three different methods. It was iododestannylated with 127, 125 or 123 iodine to obtain the corresponding iodinated and radioiodinated derivatives used for *in vitro* and *in vivo* characterization of the dopamine transporter site (11,12).

RESULTS AND DISCUSSION

β-CDIT **7a** and its radioiodinated analogues [^{125}I] β-CDIT **7b** and [^{123}I] β-CDIT (**7c**) were synthesized from natural (-) cocaine **1** as described in Scheme 1. The starting material (ecgonidine alkyl ester) was prepared by hydrolysis of (-) cocaine **1**. The resulting compound was then reacted with phosphorous oxychloride and was treated with the corresponding alcohol according to 13. Ecgonidine methyl ester **2** was obtained by this method using methanol as the alkylating agent. The Michael addition of 3, 4-dichlorophenyl magnesium bromide to α, β-ethylenic ester **2**, at -40°C in diethylether, followed by a quenching procedure with trifluoroacetic acid at -78°C, gave a mixture of 2α- and 2β-carbomethoxy-3β-(3', 4'-dichlorophenyl) tropanes **3** and **3'** respectively. These reactions were first reported by Clarke *et al.* (13) and were improved by Carroll *et al* (14). Compound **3** was then separated from its epimer **3'** by flash chromatography and characterized by ^{1}H NMR at 200 MHz. For compound **3** the axial hydrogen H-4β, observed at 2.36 ppm, was deshielded by the axial methylester function in the 2β position. By comparison, the equatorial hydrogen H-4α, further away from the ester function, displayed a signal between 1.44 and 1.68 ppm which overlapped with the resonance signals of hydrogens H-6α and H-7α. The axial hydrogen H-4β exhibited a characteristic triplet of doublets due to coupling with the equatorial hydrogen H-5 for the doublet ($^3J_{4β,5}$= 2.9 Hz), and with the equatorial hydrogen H-4α and the axial hydrogen H-3 for the triplet ($^2J_{4α,4β}$= $^3J_{3,4β}$= 12.0 Hz). The singlets of the methyl groups were observed at 2.14 ppm for the N-methyl substituent and at 3.45 ppm for the methylester function. The product (3) possessed the same absolute configuration as natural (-) cocaine. N-demethylation of the compound (3) was accomplished by conversion to its carbamate using 2,2,2-trichloroethyl chloroformate followed by zinc-acetic acid reduction to supply compound **4** according to the general procedure previously described by Clarke et al (13). Three methods were developed

from nortropane **4** for the preparation of the tributyltin precursor **6**. For methods e and f, N-

(prop-2-ynyl)-2β-carbomethoxy-3β-(3', 4'-dichlorophenyl) nortropane **5** was first synthesized

by N-alkylation of the nortropane derivative **4** with propargyl bromide. Hydrostannylation of

the alkynyl derivative **5** with tributyltin hydride in the presence of AIBN as catalyst in

toluene, yielded a 3/1 mixture of *E*-isomer **6** and *Z*-isomer **6'** N-(3-tributylstannyl-2-enyl)-2β-

carbomethoxy-3β-(3', 4'-dichlorophenyl) nortropane (route e). The *E*-tributyltin isomer **6** was

isolated from this mixture by flash chromatography using petroleum ether (40-65°C) / ethyl

acetate: 90/10 v/v (49% yield). The same results were reported in the literature (6) for the

hydrostannylation of N-(prop-2-ynyl)-2β-carbomethoxy-3β-(4'-chlorophenyl) nortropane.

Another method for the preparation of the *E*-tributyltin precursor **6** from the N-prop-2-

ynylnortropane derivative **5** consists of addition of Lipshutz reagent *n*-Bu$_3$SnCuBu(CN)Li$_2$ to

the triple bond at -78°C (15). Using this method, a 13% yield of the pure *E*-tributyltin

derivative **6** was obtained after purification by flash chromatography, as described above. In

order to improve the yield of the tin precursor **6** a third method was checked consisting of a

reaction of (*E*)-3-(tributylstannyl)prop-2-enyl chloride with nortropane **4**, according to a

similar method described by Goodman *et al.* (6). By method g, a 50% yield of the *E*-

tributyltin precursor **6** was obtained. Characterization of the *E*-tributylstannylpropenyl

nortropane derivative **6** by ¹H NMR at 200 MHz confirmed the expected structure. In

particular, hydrogens H-9 and H-9' of the CH$_2$ in the N-propenyl chain did not have the same

chemical shift (δ_9=3.06 ppm, $\delta_{9'}$ is localized in the range 2.72-2.93 ppm). This magnetic

difference was attributed to the steric hindrance of the N-stannylpropenyl group. The olefinic

hydrogens displayed a high resolution ABXX' structure in the range 5.68-6.01 ppm with a

trans coupling constant ³J= 19.1 Hz. Iododestannylation of the tributyltin precursor **6** yielded

77% β-CDIT **7a**.

Scheme 1: Synthesis of (*E*)-N-(3-iodoprop-2-enyl)-2ß-carbomethoxy-3ß-(3',4'-dichlorophenyl) nortropane **7a** and its radioiodinated analogues [^{125,123}I] ß-CDIT **7b**, **7c** from cocaine.

a)1) 0.75N HCl, 3h, reflux; 2) POCl$_3$, overnight, reflux; 3) MeOH, 4 days, r.t.: 74%. b)1) 3,4-Cl$_2$C$_6$H$_3$MgBr, Et$_2$O, 3h, -40°C; 2) F$_3$CCO$_2$H, 1h, -78°C; 3) HCl, 0°C, isomer 3 : 44%. c)1) Cl$_3$CCH$_2$OCOCl, 75min, 120°C; 2) Zn, AcOH, overnight, r.t.: 87%. d)1) HC≡CCH$_2$Br, KI, EtOH, overnight, reflux; 2) NaHCO$_3$: 76%. e)HSnBu$_3$, AIBN, toluene, overnight, reflux : 49%. f)1) Bu$_3$SnCu(Bu)CNLi$_2$, THF, 10min, -90°C; 2) NH$_4$Cl : 13%. g)1) *E*-Bu$_3$SnCH=CHCH$_2$Cl, KI, EtOH, overnight, reflux; 2) NaHCO$_3$: 50%. e) I$_2$, CHCl$_3$: 77%. f)1) [^{125}I] NaI or [^{123}I] NaI, H$_2$O$_2$, EtOH, HCl, 20min, r.t.; 2) Na$_2$S$_2$O$_5$; 3) NaHCO$_3$: >60%.

This compound retained the absolute configuration of (-) cocaine at C-2 and C-3.

Characterization by ^{1}H NMR allowed assignment of the triplet of the doublet at 2.48 ppm of

the hydrogen H-4β ($^3J_{4\beta,5}$=2.9 Hz, $^2J_{4\alpha,4\beta}$=$^3J_{3,4\beta}$= 12.4 Hz), the singlet at 3.45 ppm of the 2β-

methylester function, the doublet at 6.13 ppm of the olefinic hydrogen H-11 and the doublet

of triplets at 6.41 ppm of the olefinic hydrogen H-10 in trans position to each other ($^3J_{10,11}$=

14.5 Hz) due to retention of the olefinic configuration during the iodine-metal exchange. The

radioiodinated compounds [^{125}I] β-CDIT **7b** and [^{123}I] β-CDIT **7c** were prepared by

iododestannylation of the stannyl derivative **6** using radiolabelled sodium iodide [^{125}I] or [^{123}I]

respectively and 3% w/v hydrogen peroxide as oxidizing agent at room temperature according

to a general radiolabelling method (6).The radioiodinated products [^{125}I] β-CDIT **7b** or [^{123}I]

β-CDIT **7c** were isolated by HPLC on a RP18 column using methanol / water / triethylamine

(75/25/0.2) as eluent and compared to their corresponding unlabelled analogues **7a** by HPLC

with simultaneous UV and radioactivity detection as presented in Figure 1. It was shown to be

Figure 1 : HPLC analysis by coinjection of iodinated **7a** and [^{125}I] radioiodinated **7b**

β-CDIT into a RP18 column using MeOH / H$_2$O / Et$_3$N : 75 / 25 / 0.2 as eluent.

the expected product on the basis of the elution profile. Radiolabelling yield after HPLC purification was > 60%.

This paper describes the synthesis of iodinated and radioiodinated ß-CDIT. These compounds were obtained by iododestannylation of the corresponding tributyltin precursor which was prepared by three different methods. ß-CDIT labelled with 125 or 123 iodine was obtained with good radiochemical yields (>60%) with a radiochemical purity >95% and specific radioactivity of 2200 Ci / mmol for [^{125}I] ß-CDIT. [^{125}I] ß-CDIT was used for *in vitro* and *in vivo* characterization in rats (11) and [^{123}I] ß-CDIT was used for *in vivo* examination of the dopamine transporter site in monkeys (12).

EXPERIMENTAL PART

Cocaine hydrochloride was purchased from Coopération Pharmaceutique Française; *n*-butyl-lithium 1.6M solution in hexane, propargyl alcohol, tributyltin hydride, 2,2,2-trichloroethylchloroformate, trifluoroacetic acid and zinc from Aldrich; triphenylphosphine from Acros; 1-bromo-3,4-dichlorobenzene from Lancaster; α,α'-azoisobutyronitrile (AIBN) from Merck; copper (I) cyanide, iodine, magnesium, phosphorus oxychloride, potassium iodide, triethylamine from Prolabo; [^{125}I] NaI from Amersham (in NaOH 0.1N solution, specific activity = 2200 Ci/mmol) and [^{123}I] NaI from Cis Bio International (in NaOH 0.1N solution, specific activity > 5000 Ci/mmol). All reagents were used without purification and solvents were usually distilled and dried. Thin layer chromatography analyses were conducted using silica gel 60F254 TLC plates (Merck) and compounds were revealed by UV detection or iodine chamber. Flash chromatography was used for routine purification of reaction products using silica gel 230-400 Mesh (Merck) ASTM. HPLC was performed on a Beckman 331 isocratic liquid chromatograph fitted with UV at 254 nm and a radioactivity detector, using a reverse phase 10RP18 column (25 cm × 4.6 mm) from Chrompack. NMR spectra were recorded on a Brüker Avance DPX 200 spectrometer (at 200 MHz for ^{1}H and 50 MHz

for ^{13}C) using CDCl$_3$ as solvent. Chemical shifts were expressed in ppm relative to tetramethylsilane as internal standard. Mass spectra were obtained on a CG-MS Hewlett Packard 5989A spectrometer (electronic impact at 70 eV). The purity of the synthesized compounds was verified by gas chromatography (CG, HP 5890A, II) coupled with a mass spectrometer. A 25 m × 0.2 mm fused silica capillary column OVI (HP1) (Hewlett Packard) was directly inserted into the ion source of the HP quadrupole mass spectrometer through a heated (250°C) interface box. Helium was used as carrier gas with a flow rate through the column of 0.7 mL / min. The temperature remained at 70°C for 1 min and was then programmed up to 300°C at 10°C / min. The experimental time was 1 hour. The temperature of the ion source was 200°C. For target compound **7a**, elemental analyses were within ± 0.4% of the theoretical values and were determined in the Laboratory of the Service Central d'Analyses du CNRS (Vernaison, France).

*Ecgonidine methyl ester **2**:*

Ecgonidine methyl ester was prepared according to the method described in the literature (13, 16). Cocaine hydrochloride **1** (20 g, 58 mmol) was refluxed with 0.75 N HCl solution (200 mL) for 3 hours. The reaction was cooled to room temperature and extracted with Et$_2$O (2 × 30 mL) in order to remove the benzoic acid obtained as by-product. The aqueous solution was evaporated to dryness and refluxed overnight with POCl$_3$ (40 mL). Excess POCl$_3$ was removed by distillation *in vacuo*. The residue was treated with MeOH (400 mL) and stirred at room temperature for one week. The methanolic solution was evaporated, brought to basic pH with a solution of K$_2$CO$_3$ 10% (100 mL), extracted with Et$_2$O (4 × 25 mL), washed with brine, dried with Na$_2$SO$_4$ and the solvent was evaporated. Distillation of the residue (45-47°C/ 0.2 torr) yielded 72% pure product **2** (7.4 g, 41 mmol).

^{1}H NMR (CDCl$_3$): δ = 1.26-1.32 (m, 1H, H-6α); 1.55-1.66 (m, 2H, H-4α, H-7α); 1.90-1.95 (m, 2H, H-6β, H-7β); 2.11 (s, 3H, NCH$_3$); 2.35-2.44 (m, 1H, H-4β); 3.01 (m, 1H, H-5); 3.49 (s, 3H, OCH$_3$); 3.55 (m, 1H, H-1); 6.58 (m, 1H, H-3). ^{13}C NMR (CDCl$_3$): δ = 30.2 (C-6), 31.7

(C-7), 34.5 (C-4), 36.4 (NCH$_3$), 51.6 (OCH$_3$), 57.0 (C-5), 58.6 (C-1), 134.1 (C-2), 135.9 (C-3), 166.5 (CO$_2$).

2β-Carbomethoxy-3β-(3',4'-dichlorophenyl) tropane **3**:

According to a previously reported method (13), compound **3** was prepared from ecgonidine methyl ester **2** and 3,4-dichlorophenylmagnesium bromide in dry Et$_2$O. The Grignard reagent was prepared from Mg (1.2 g, 50 mmol), 1-bromo-3,4-dichlorobenzene (11.3 g, 50 mmol) in Et$_2$O (40 mL). Compound **2** (1.5 g, 8.3 mmol) in dry Et$_2$O (25 mL) was added dropwise to a vigorously stirred solution of 3,4-dichlorophenylmagnesium bromide under dry N$_2$ at -40°C and stirring was continued at -40°C for 3 hours. The solution was further cooled to -78°C and treated with 5.8 mL of trifluoroacetic acid dissolved in 25 mL of dry Et$_2$O and stirred for one hour. The mixture was brought to 0°C and diluted with water (40 mL). The aqueous phase was separated and acidified with a concentrated HCl solution (17 mL) and the organic layer was separated. The aqueous layer was treated with a solution of concentrated NH$_4$OH (90 mL) to basic pH at 0°C and extracted with Et$_2$O (3 × 30 mL). This solution was dried and evaporated to yield a residue which was purified by flash chromatography (Et$_2$O/Et$_3$N: 9/1 v/v). A yield of 44% of the product **3** was obtained (1.1 g).

^{1}H NMR (CDCl$_3$): δ = 1.44-1.68 (m, 3H, H-4α, H-6α, H-7α); 1.94-2.22 (m, 2H, H-6β, H-7β); 2.14 (s, 3H, NCH$_3$); 2.36 (td, 1H, $^3J_{4\beta,5}$ = 2.9 Hz, $^2J_{4\alpha,4\beta}$ = $^3J_{3,4\beta}$ =12.0 Hz, H-4β); 2.78-2.91 (m, 2H, H-2, H-3); 3.27 (m, 1H, H-5); 3.45 (s, 3H, OCH$_3$); 3.49 (m, 1H, H-1); 7.02 (dd, 1H, $^3J_{5',6'}$ = 8.4 Hz, $^4J_{2',6'}$ = 2.0 Hz, H-6'); 7.23 (2d, 2H, $^3J_{5',6'}$ = 8.4 Hz, $^4J_{2',6'}$ = 2.0 Hz, H-2', H-5'). ^{13}C NMR (CDCl$_3$): δ = 25.6 (C-6), 26.2 (C-7), 33.6 (C-3), 34.3 (C-4), 42.3 (NCH$_3$), 51.7 (OCH$_3$), 52.9 (C-2), 62.5 (C-5), 65.6 (C-1), 127.2 (C-6'), 129.8 (C-2'), 130.0 (C-4'), 130.2 (C-5'), 132.2 (C-3'), 144.1 (C-1'), 172.2 (CO$_2$). MS (EI): m/z = 331 (1%, C$_{16}$H$_{19}$^{37}Cl$_2$NO$_2$$^+$), 329 (6%, C$_{16}H_{19}$^{37}Cl^{35}ClNO$_2$$^+$), 327 (9%, C$_{16}H_{19}^{35}Cl_2NO_2$$^+$), 300 (1%, C$_{15}H_{16}^{37}Cl_2NO^+$), 298 (2%, C$_{15}H_{16}$^{37}Cl^{35}ClNO$^+$), 296 (2%, C$_{15}H_{16}^{35}Cl_2NO^+$), 270 (3%, C$_{14}H_{16}$^{37}Cl^{35}ClN$^+$), 268 (4%, C$_{14}H_{16}^{35}Cl_2N^+$), 242 (1%, C$_{12}H_{12}$^{37}Cl^{35}ClN$^+$), 240 (3%, C$_{12}H_{12}^{35}Cl_2N^+$), 155 (5%, C$_8H_{13}NO_2$$^+$),

154 (1%, $C_8H_{12}NO_2^+$), 97 (34%, $C_6H_{11}N^+$), 96 (43%, $C_6H_{10}N^+$), 83 (100%, $C_5H_9N^+$), 82 (94%, $C_5H_8N^+$), 59 (2%, $CO_2CH_3^+$).

*2β-Carbomethoxy-3β-(3',4'-dichlorophenyl) nortropane **4***:

According to reported procedures (13, 17), the tropane derivative **3** (656 mg, 2 mmol) was treated with 2,2,2-trichloroethyl chloroformate (1.2 mL, 11 mmol). The mixture was heated at 120°C for 75 min under nitrogen atmosphere. After cooling, the excess of reagent was distilled *in vacuo* (60-62°C / 15 torr) yielding the crude carbamate which was dissolved in 95% acetic acid (15 mL) containing freshly activated zinc dust (1.6 mg, 24.4 mmol) and stirred at room temperature for 24h. The solution was filtered with celite, treated with a 10% NaOH solution and extracted with $CHCl_3$ to yield the crude product which was purified by flash chromatography using Et_2O / Et_3N: 9/1 as eluent. The pure product **4** (526 mg, 84%) was a waxy substance.

^1H NMR ($CDCl_3$): δ = 1.53-1.73 (m, 3H, H-4α, H-6α, H-7α); 1.93-2.07 (m, 2H, H-6β, H-7β); 2.29 (td, 1H, $^3J_{4β,5}$ = 2.8 Hz, $^2J_{4α,4β}$ = $^3J_{3,4β}$ =12.8 Hz, H-4β); 2.77 (dd, 1H, $^3J_{1,2}$ = 1.6 Hz, $^3J_{2,3}$ = 5.9 Hz, H-2); 3.14 (dt, 1H, $^3J_{2,3}$ = $^3J_{3,4α}$ = 5.9 Hz, $^3J_{3,4β}$ = 12.8 Hz, H-3); 3.37 (s, 3H, OCH_3); 3.66 (m, 2H, H-1, H-5); 6.56 (bs, 1H, NH); 6.97 (dd, 1H, $^3J_{5',6'}$ = 8.2 Hz, $^4J_{2',6'}$ = 2.0 Hz, H-6'); 7.11 (d, 1H, $^4J_{2',6'}$ = 2.0 Hz, H-2'); 7.18 (d, 1H, $^3J_{5',6'}$ = 8.2 Hz, H-5'). ^{13}C NMR ($CDCl_3$): δ = 26.3 (C-6), 27.6 (C-7), 32.1 (C-4), 34.9 (C-3), 49.6 (C-2), 52.5 (OCH_3), 54.5 (C-5), 56.1 (C-1), 127.2 (C-6'), 129.8 (C-2'), 130.8 (C-5'), 131.6 (C-4'), 132.9 (C-3'), 140.7 (C-1'), 173.3 (CO_2).

*N-(prop-2-ynyl)-2β-carbomethoxy-3β-(3',4'-dichlorophenyl) nortropane **5***:

A solution of propargyl bromide 80% in toluene (75 mL, 673 μmol) was added to a solution of the nortropane derivative **4** (163.6 mg, 60 μmol) in absolute EtOH containing a catalytic amount of potassium iodide. The mixture was refluxed overnight and the solvent evaporated under reduced pressure. Water (20 mL) was added to the residue and the mixture was brought

to basic pH with NaHCO$_3$, extracted with Et$_2$O, dried over Na$_2$SO$_4$ and the solvent was evaporated. After flash chromatography (Et$_2$O / Et$_3$N: 95/5) the pure compound **5** was isolated as a waxy substance (140 mg, 78%)

^{1}H NMR (CDCl$_3$): δ = 1.52-1.80 (m, 3H, H-4α, H-6α, H-7α); 1.89-2.30 (m, 2H, H-6β, H-7β); 2.09 (t, 1H, $^4J_{9,11}$ = 2.4 Hz, H-11); 2.49 (td, 1H, $^3J_{4\beta,5}$ = 2.5 Hz, $^2J_{4\alpha,4\beta}$ = $^3J_{3,4\beta}$ =12.0 Hz, H-4β); 2.78-2.94 (m, 2H, H-2, H-3); 3.04 (AA'X, 2H, $^2J_{9,9'}$ = 16.2 Hz, $^4J_{9,11}$ = 2.5 Hz, H-9, H-9'); 3.44 (m, 1H, H-5); 3.47 (s, 3H, OCH$_3$); 3.90 (m, 1H, H-1); 7.03 (dd, 1H, $^3J_{5',6'}$ = 8.3 Hz, $^4J_{2',6'}$ = 2.0 Hz, H-6'); 7.25 (2d, 2H, $^4J_{2',6'}$ = 2.0 Hz, $^3J_{5',6'}$ = 8.3 Hz, H-2', H-5').

(E)-3-tributylstannylprop-2-en-1-ol:

This compound was prepared according to the procedure described in the literature (18). Propargyl alcohol (8.5 mL, 146 mmol) was heated to 100°C overnight with HSnBu$_3$ (52 mL, 187 mmol) and a catalytic amount of AIBN. Flash chromatography with petroleum ether (40-60°C) / EtOAc: 9/1 v/v yielded pure (*E*)-3-tributylstannylprop-2-en-1-ol as a colourless oil (39.6 g, 78%).

^{1}H NMR (CDCl$_3$): δ = 0.87 [t, 15H, ^3J = 8.6 Hz, 3CH$_3$, (-CH$_2$)$_3$Sn]; 1.27-1.68 (m, 12H, 3 CH$_2$CH$_2$); 2.46 (t, 1H, ^3J = 5.6 Hz, OH); 4.16 (dd, 2H, ^3J = 5.6 Hz, ^3J = 3.0 Hz, CH$_2$C=); 6.08-6.29 (ABX$_2$, 2H, $^3J_{AB}$ = 19.0 Hz, $^3J_{BX}$ = 3.0 Hz, CH=CH).

(E)-3-tributylstannylprop-2-enyl chloride:

This compound was prepared according to the procedure described in the literature (6). (*E*)-3-tributylstannylprop-2-en-1-ol (813 mg, 2.34 mmol) was dissolved in CCl$_4$ (4.5 mL) containing triphenylphosphine (750 mg, 2.86 mmol) and the reaction mixture was heated at 60°C in a sealed vial for 48 h. CCl$_4$ was evaporated and the product was purified by flash chromatography using petroleum ether (40-60°C) / Et$_3$N: 98/2 v/v yielded pure (*E*)-3-tributylstannylprop-2-enyl chloride (599 mg, 70%) as a colourless oil.

^{1}H NMR (CDCl$_3$): δ = 0.95 [t, 15H, 3CH$_3$, (-CH$_2$)$_3$Sn]; 1.29-1.71 (m, 12H, 3 CH$_2$CH$_2$); 4.10

(dd, 2H, ^3J = 6.0 Hz, ^4J = 1.0 Hz, ClCH$_2$C=); 6.10 (dt, 1H, ^3J = 18.7 Hz, ^3J = 6.0 Hz, CH=);

6.35 (dt, 1H, ^3J = 18.7 Hz, ^4J = 1.0 Hz, SnCH=).

(E)-N-(3-tributylstannylprop-2-enyl)-2β-carbomethoxy-3β-(3',4'-dichlorophenyl) nortropane

6:

Method e: [as described in the literature (6)]: The N-propargylnortropane derivative **5** (100

mg, 286 mmol) was dissolved in toluene (1.5 mL) containing 97% HSnBu$_3$ (168 mg, 560

µmol) and AIBN (14 mg). The reaction mixture was heated at 90°C for 5 hours, blanketed

under dry nitrogen atmosphere. The solvent was then removed *in vacuo* and the residue

purified by flash chromatography using Et$_2$O / Et$_3$N: 9 / 1 v/v as eluent. Purification of the

(*E*)-tin isomer **6** was then performed on preparative silica gel TLC 60F254 Merck using

petroleum ether (40-65°C) / EtOAc: 9 / 1 v/v as eluent. Rf **5** = 0.10, Rf *E*-isomer **6** = 0.25, Rf

Z-isomer **6'** = 0.55. The *E*-isomer **6** (86.2 mg, 49%) was obtained as a colourless oil.

Method f: [as described in the literature (15)]: Lipshutz reagent was prepared from a

suspension of CuCN (66 mg, 737 µmol) in tetrahydrofuran (2mL) which was cooled to -90°C,

blanketed under nitrogen atmosphere. Then 1.6M *n*-BuLi solution in hexanes (1 mL, 1.6

mmol) was added dropwise to form the complex nBu$_2$Cu(CN)Li$_2$. The mixture was allowed to

stand for 15 min at -90°C to yield a colourless solution. Tri-*n*-butyltin hydride (430 µL, 1.6

mmol) was added dropwise with a syringe. Stirring was continued for 10 min at the same

temperature until the solution yellowed and H$_2$ gas was liberated. N-propargylnortropane

derivative **5** (212 mg, 607 µmol) was added neat. The reaction mixture was stirred for 10 min

at -90°C and quenched with a solution of NH$_4$Cl 1M (10 mL). Extraction with Et$_2$O (3 × 20

mL) was followed by drying the organic phase over Na$_2$SO$_4$. The solvent was removed *in*

vacuo and the residue purified by flash chromatography using petroleum ether (40-65°C) /

AcOEt: 9 / 1 v/v as eluent. (*E*)-N-tributylstannylprop-2-enylnortropane derivative **6** (51 mg,

13%) was separated from its gem isomer.

Method g: (*E*)-3-tributylstannylprop-2-enyl chloride (110 mg, 301 μmol) was added to a

solution of nortropane derivative **4** (95 mg, 304 μmol) in absolute EtOH (3 mL) containing a

catalytic amount of KI (5 mg, 30 μmol). The reaction mixture was refluxed overnight. The

solvent was evaporated under *vacuum* and the residue was treated with H_2O (15 mL) and then

brought to alkaline pH with a 5% $NaHCO_3$ solution. The aqueous phase was extracted with

Et_2O (3 × 10 mL). Combined organic layers were dried over Na_2SO_4. After removing the

solvent, the product was purified by flash chromatography using petroleum ether / EtOAc: 9 /

1 as eluent. *E*-isomer **6** (96 mg, 50%) was obtained as a colourless oil.

^1H NMR *E*-isomer **6** (CDCl$_3$): δ= 0.82 (t, 9H, ^3J= 7.0 Hz, 3CH$_3$); 1.10-1.62 [m, 21H, (-

CH$_2$CH$_2$CH$_2$)$_3$Sn, H-4α, H-6α, H-7α]; 1.98 (m, 2H, H-6ß, H-7ß); 2.48 (td, 1H, $^3J_{4\text{ß},5}$= 2.9Hz,

$^2J_{4\alpha,4\text{ß}}$= $^3J_{3,4\text{ß}}$= 12.4Hz, H-4ß); 2.72-2.93 (m, 3H, H-2, H-3, H-9'); 3.06 (dd, 1H, $^2J_{9,9'}$= 13.5Hz,

$^3J_{9,10}$= 3.7Hz, H-9); 3.35 (m, 1H, H-5); 3.45 (s, 3H, OCH$_3$); 3.64 (m, 1H, H-1); 5.68-6.01

(ABXX', 2H, $^3J_{10,11}$= 19.1Hz, $^3J_{9',10}$= 5.9Hz, $^3J_{9,10}$= 3.7Hz, CH=CH); 7.05 (dd, 1H, $^3J_{5',6'}$=

8.3Hz, $^4J_{2',6'}$= 2.0Hz, H-6'); 7.25 (d, 1H, $^3J_{5',6'}$= 8.3Hz, H-5'); 7.26 (d, 1H, $^4J_{2',6'}$= 2.0Hz, H-2').

^1H NMR *Z*-isomer (6) (CDCl$_3$): δ= 0.83 (t, 9H, ^3J= 7.1 Hz, 3CH$_3$); 1.19-2.10 [m, 23H, (-

CH$_2$CH$_2$CH$_2$)$_3$Sn, H-4α, H-6α, H-6ß, H-7α, H-7ß]; 2.47 (td, 1H, $^3J_{4\text{ß},5}$= 3.0Hz, $^2J_{4\alpha,4\text{ß}}$= $^3J_{3,4\text{ß}}$=

12.2Hz, H-4ß); 2.66-2.93 (m, 4H, H-2, H-3, H-9, H-9'); 3.35 (m, 1H, H-5); 3.45 (s, 3H,

OCH$_3$); 3.64 (m, 1H, H-1); 5.86 (d, 1H, $^3J_{10,11}$= 12.7Hz, H-11); 6.35 (ddd, 1H, $^3J_{10,11}$= 12.7Hz,

$^3J_{9,10}$= 7.0Hz, $^3J_{9',10}$= 4.6Hz, H-10); 7.04 (dd, 1H, $^3J_{5',6'}$= 8.3Hz, $^4J_{2',6'}$= 2.0Hz, H-6'); 7.23 (m,

2H, H-2', H-5').

(E)-N-(3-iodoprop-2-enyl)-2β-carbomethoxy-3β-(3',4'-dichlorophenyl) nortropane **7a**:

A solution of the *E*-tin precursor **6** (200 mg, 310 μmol) in CHCl$_3$ (2 mL) was cooled to 0-5°C.

A 0.1 N iodine solution in CHCl$_3$ was then added dropwise to the stirred mixture until a

coloured solution was obtained. The organic phase was washed with brine (2 × 1 mL) and

dried over Na$_2$SO$_4$. The solvent was removed *in vacuo* and the crude product purified by flash

chromatography using Et$_2$O / Et$_3$N (95 / 5 v / v) as eluent. TLC analyses were carried out with

Et$_2$O / Et$_3$N (95 / 5), Rf **7a** = 0.98. The *E*-iodinatednortropane derivative **7a** (77 mg, 52%) was

obtained as an oil. Anal. (C$_{18}$H$_{20}$Cl$_2$INO$_2$) calc.: C, 45.0, H, 4.2, N, 2.9. Found: C, 44.6, H, 4.1,

N, 2.5%.

^{1}H NMR (CDCl$_3$): δ= 1.52-1.72 (m, 3H, H-4α, H-6α, H-7α); 1.83-2.02 (m, 2H, H-6ß, H-7ß);

2.46 (td, 1H, $^3J_{4ß,5}$= 2.8Hz, $^2J_{4α,4ß}$= $^3J_{3,4ß}$= 12.0Hz, H-4ß); 2.68-2.92 (m, 4H, H-2, H-3, NCH$_2$-);

3.33 (m, 1H, H-5); 3.49 (s, 3H, OCH$_3$); 3.61 (m, 1H, H-1); 6.13 (d, 1H, $^3J_{10,11}$= 14.5Hz, H-11);

6.41 (dt, 1H, $^3J_{9,10}$= 6.6Hz, $^3J_{10,11}$= 14.5Hz, H-10); 7.03 (dd, 1H, $^3J_{5',6'}$= 8.3Hz, $^4J_{2',6'}$= 2.1Hz, H-

6'); 7.25 (d, 1H, $^4J_{2',6'}$= 2.1Hz, H-2'); 7.26 (d, 1H, $^3J_{5',6'}$= 8.3Hz, H-5'). ^{13}C NMR: δ= 26.2 (C–

6), 26.4 (C-7), 34.0 (C-3), 34.2 (C-4), 51.8 (OCH$_3$), 52.7 (C-2), 58.3 (C-9), 61.5 (C-5), 62.7

(C-1), 77.6 (C-11), 126.7 (C-6'), 129.4 (C-2'), 129.6 (C-4'), 129.7 (C-5'), 131.7 (C-3'), 143.2

(C-1'), 143.8 (C-10), 171.3 (CO$_2$). MS (EI): m/z = 481 (9%, C$_{18}$H$_{20}$^{35}Cl^{37}ClINO$_2$$^+$); 479 (10%,

C$_{18}$H$_{20}$^{35}Cl$_2$INO$_2$$^+$); 450 (2%, C$_{17}H_{17}$^{35}Cl^{37}ClINO$^+$); 448 (3%, C$_{17}H_{17}^{35}Cl_2INO^+$); 422 (3%,

C$_{16}$H$_{17}$^{35}Cl^{37}ClIN$^+$); 420 (7%, C$_{16}$H$_{17}$^{35}Cl$_2$IN$^+$); 356 (7%, C$_{18}$H$_{20}$^{37}Cl$_2$NO$_2$$^+$); 354 (38%,

C$_{18}$H$_{20}$^{35}Cl^{37}ClNO$_2$$^+$); 352 (60%, C$_{18}H_{20}^{35}Cl_2NO_2$$^+$); 324 (3%, C$_{17}H_{16}^{37}Cl_2NO^+$); 322 (9%,

C$_{17}$H$_{16}$^{37}Cl^{35}ClNO$^+$); 320 (16%, C$_{17}$H$_{16}$^{35}Cl$_2$NO$^+$); 316 (2%, C$_{15}$H$_{16}$^{37}Cl$_2$NO$_2$$^+$); 314 (4%,

C$_{15}$H$_{16}$^{37}Cl^{35}ClNO$_2$$^+$); 312 (6%, C$_{15}H_{16}^{35}Cl_2NO_2$$^+$); 307 (3%, C$_{10}H_{14}INO_2$$^+$); 296 (1%,

C$_{16}$H$_{16}$^{37}Cl$_2$N$^+$); 294 (7%, C$_{16}$H$_{16}$^{37}Cl^{35}ClN$^+$); 292 (10%, C$_{16}$H$_{16}$^{35}Cl$_2$N$^+$); 249 (4%, C$_8$H$_{12}$IN$^+$);

248 (20%, C$_8$H$_{11}$IN$^+$); 235 (54%, C$_7$H$_{10}$IN$^+$); 234 (54%, C$_7$H$_9$IN$^+$); 180 (24%, C$_{10}$H$_{14}$NO$_2$$^+$);

167 (94%, C$_3$H$_4$I$^+$); 68 (100%, C$_4$H$_6$N$^+$).

(E)-N-(3-[$^{125/123}$-I]iodoprop-2-enyl)-2ß-carbomethoxy-3ß-(3',4'-dichlorophenyl)nortropanes

7b and **7c**:

According to a radiolabelling method (6), [^{125}I] ß-CDIT **7b** and [^{123}I] ß-CDIT **7c** were prepared

in a vial containing the stannyl precursor **6** (50 μg), EtOH (50 μL), 0.1N HCl aqueous

solution (50 μL), [^{125}I] NaI (1 mCi) or [^{123}I] NaI (2 mCi) and 3% w/v H$_2$O$_2$ (50 μL). After 20

min at room temperature, the reaction was stopped with 15M Na$_2$S$_2$O$_5$ aqueous solution (100

μL), brought to basic pH with 5% NaHCO$_3$ and extracted with AcOEt (3 × 1 mL). After

separation the organic layer was evaporated under a nitrogen stream. Isolation of the radiolabelled compounds **7b** and **7c** was performed by HPLC on a RP18 column using MeOH / H_2O / Et_3N: 75 / 25 / 0.2 v/v/v as mobile phase (flow rate= 1 mL / min). To be injected, the residue was dissolved in the mobile phase (100 µL). The fraction eluted at the retention time of 12 min for the radioiodinated derivatives **7b** and **7c** was collected, introduced into a C18 SepPak cartridge and eluted with EtOH (2 × 1 mL). The solvent was evaporated under a nitrogen stream. The radiolabelled ligand **7b** or **7c** was obtained with a radiochemical purity > 95%, and 60% radiochemical yield.

ACKNOWLEDGEMENTS

REFERENCES

1. Hornykiewcz, O.- Pharmacol. Rev. **18**: 925-961 (1966)

2. Allard P., Marcusson J.O.- Neurobiol. Aging **10**: 661-664 (1989)

3. Snyder, S.H.- Am. J. Psychiatry **138**: 460-464 (1984)

4. Neumeyer, J.L., Wang, S., Milius, R.A., Baldwin, R.M., Zea-Ponce, Y., Hoffer, P.B., Sybirska, E., Al-Tikriti, M., Charney, D.S., Malison, R.T., Laruelle, M. and Innis, R.B.- J. Med. Chem. **34**: 3144-3146 (1991)

5. Baldwin, R.M., Zea-Ponce, Y., Zoghbi, S.S., Laurelle, M., Al-Tikriti, M.S., Sybirska, E.H., Malison, R.T., Neumeyer, J.L., Milius, R.A., Wang, S., Stabin, M., Smith, E.O., Charney, D.S., Hoffer, P.B. and Innis, R.B.- Nucl. Med. Biol. **20**: 597-606 (1993)

6. Goodman, M.M., Kung, M.-P., Fabalka, G.W., Kung, H.F. and Switzer, R.- J. Med. Chem. **37**: 1535-1542 (1994)

7. Neumeyer, J.L., Wang, S., Gao, Y., Milius, R.A., Kula, N.S., Campbell, A., Baldessarini, R.J., Zea-Ponce, Y., Baldwin, R.M. and Innis, R.B.- J. Med. Chem. **37**: 1558-1561 (1994)

8. Ametamey, S.M., Halldin, C., Swahn, C.-G., Hall, H., Schubiger, P.A. and Farde, L.- Nucl. Med. Biol. **22**: 959-964 (1995)

9. Zea-Ponce, Y., Baldwin, R.M., Laruelle, M., Wang, S., Neumeyer, J.L. and Innis, R.B.- Nucl. Med. Biol. **36**: 525-529 (1995)

10. Kung, M.P., Essman, W.D., Frederick, D., Meegalla, S., Goodman, M., Mu, M., Luck, I. and Kung, H.F.- Synapse. **20**: 316-324 (1995)

11. Emond, P., Chalon, S., Garreau, L., Dognon, A.-M., Bodard, S., Frangin, Y., Baulieu, J.-L., Besnard, J.-C. and Guilloteau, D.- Synapse In press

12. Emond, P., Garreau, L., Chalon, S., Boazi, M., Frangin, Y., Besnard, J.-C. and Guilloteau, D.- J. Nucl. Med. **37**: 186P (1996)

13. Clarke, R.L., Daum, S.I., Gambino, A.J., Aceto, M.D., Pearl, J., Levitt, M., Cumiskey, W.R. and Bogado, E.F.- J. Med. Chem. **16**: 1260-1267 (1973)

14. Carroll, F.I., Gao, Y., Rahman, M.A., Abraham, P., Parham, K., Lewin, A.H., Boja, J.W. and Kuhar, M.J.- J. Med. Chem. **34**: 2719-2725 (1991)

15. Lipshutz, B.H., Ellsworth, E.L., Dimock, S.H. and Reuter, D.C.- Tetrahed. Lett. **30**: 2065-2068 (1989)

16. Meltzer, P.C., Liang, A.Y., Brownell, A.-L., Elmaleh, D.R. and Madras, B.K.- J. Med. Chem. **36**: 855-862 (1993)

17. Milius, R.A., Saha, J. K., Madras, B.K. and Neumeyer, J.L.- J. Med. Chem. **34**: 1728-1731 (1991)

18. Jung, M.E. and Light, L.A.- Tetrahed. Lett. **23**: 3851-3854 (1982)